Pancreatic Cancer Research

ResearcherAsahikawa Medical UniversityActive in the last 2 years

Takahiro Einama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4434-0803; OpenAlex author ID A5031184711. Sources: OpenAlex.

Their work

Papers
24 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 4 papers · 2025: 6 papers · 2026: 3 papers

Papers 24

  1. Radiologic-pathologic discrepancy in the tumor size assessment of pancreatic ductal adenocarcinoma in the era of preoperative therapy. Co-author DOI 10.1007/s00595-026-03419-5↗
  2. Pancreatic cancer mimicking ectopic pancreas origin: a rare case after neonatal pyloromyotomy. Co-author DOI 10.1007/s12328-026-02352-x↗
  3. Clinical benefit of locoregional therapy for oligometastasis after surgery for pancreatic cancer: a single center retrospective study. First author DOI 10.1186/s12885-026-16566-2↗
  4. Risk of hepatic steatosis with the preoperative treatment of pancreatic cancer and the short-term postoperative outcomes. Co-author DOI 10.1007/s00595-024-02895-x↗
  5. Prognostic impact of dose reduced S-1 adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: a retrospective multicenter study. First author DOI 10.1007/s10147-025-02742-0↗
  6. Postoperative recurrence of pancreatic cancer controlled for 9 months solely by severe carbohydrate restriction: ketogenic diet. Co-author DOI 10.1007/s12328-025-02221-z↗
  7. A novel scoring system for prognostic stratification of node-positive pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2025.102187↗
  8. Surgery based on resectability status of pancreatic cancer: a narrative review. Co-author DOI 10.1093/jjco/hyaf131↗
  9. Dissecting Tumor Size Underestimation in Pancreatic Cancer: A Comparative Analysis of Preoperative Treatments. Co-author DOI 10.1245/s10434-025-16917-6↗
  10. Prognostic factors based on histological categorization of desmoplastic reactions in pancreatic cancer. Co-author DOI 10.1002/wjs.12269↗
  11. A case of superior mesenteric artery stenting for small intestinal ischaemia caused by superior mesenteric artery invasion of pancreatic cancer. Co-author DOI 10.1093/bjrcr/uaae031↗
  12. Preoperative CA19‑9 level and dual time point FDG‑PET/CT as strong biological indicators of borderline resectability in pancreatic cancer: A retrospective stud… First author DOI 10.3892/ol.2024.14412↗
  13. Pancreatic cancer with liver metastasis maintaining complete response with gemcitabine monotherapy: A case report. Co-author DOI 10.3892/ol.2024.14503↗
  14. Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience. Co-author DOI 10.3390/cancers15041101↗
  15. Preoperative Rapid Weight Loss as a Prognostic Predictor After Surgical Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002186↗
  16. Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study. First author DOI 10.1186/s12885-022-10116-2↗
  17. Clinical Impact of Dual Time Point 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer. Co-author DOI 10.3390/cancers14153688↗
  18. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive panc… Co-author DOI 10.1186/s12885-020-07722-3↗
  19. Pathomorphological features of metastatic lymph nodes as predictors of postoperative prognosis in pancreatic cancer. Co-author DOI 10.1097/md.0000000000014369↗
  20. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in … Co-author DOI 10.18632/oncotarget.26117↗
  21. Curative resection of pancreatic ductal adenocarcinoma developing in the remnant pancreas 13 years after distal pancreatectomy for intraductal papillary mucino… Co-author DOI 10.3892/mco.2018.1556↗
  22. PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Co-author DOI 10.1007/s12032-012-0193-0↗
  23. Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/etm.2012.518↗
  24. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e318221bed8↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoji Kishi · 16 shared papers, 2022–2026 · strength 3.59
  2. Hideki Ueno · 14 shared papers, 2019–2026 · strength 3.05
  3. Kazuki Kobayashi · 7 shared papers, 2024–2025 · strength 1.60
  4. Kazuki Kobayashi · 5 shared papers, 2022–2026 · strength 1.02
  5. Mayuko Ohara · 3 shared papers, 2024–2026 · strength 0.72
  6. Koki Ichio · 3 shared papers, 2024–2026 · strength 0.72
  7. Yoshifumi Beck · 2 shared papers, 2025 · strength 0.49
  8. Yoichi Miyata · 2 shared papers, 2025 · strength 0.49
  9. Makoto Nishikawa · 3 shared papers, 2019–2025 · strength 0.46
  10. Akifumi Kimura · 2 shared papers, 2019–2025 · strength 0.31
  11. Hirofumi Kamachi · 4 shared papers, 2011–2021 · strength 0.30
  12. Yuta Hasegawa · 1 shared paper, 2026 · strength 0.29
  13. Akinobu Taketomi · 3 shared papers, 2018–2021 · strength 0.28
  14. Junji Yamamoto · 3 shared papers, 2012–2022 · strength 0.28
  15. Hiroshi Shinmoto · 1 shared paper, 2024 · strength 0.26
  16. Hiroshi Kuwamura · 1 shared paper, 2024 · strength 0.26
  17. Mayumi Hoshikawa · 2 shared papers, 2019–2022 · strength 0.25
  18. Tatsuzo Mizukami · 2 shared papers, 2018–2021 · strength 0.21
  19. Fumihiko Matsuzawa · 2 shared papers, 2018–2021 · strength 0.21
  20. Shuji Suzuki · 1 shared paper, 2024 · strength 0.21
  21. Ryoichi Miyamoto · 1 shared paper, 2024 · strength 0.21
  22. Yuichi Nagakawa · 1 shared paper, 2024 · strength 0.21
  23. Mitsugi Shimoda · 1 shared paper, 2024 · strength 0.21
  24. Toshitaka Nagao · 1 shared paper, 2024 · strength 0.21
  25. Yuki Fujii · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.